Cervagem : A New Prostaglandin in Obstetrics and Gynaecology Proceedings of a Symposium Held at the Shangri-La Hotel, Singapore, 31 July 1982.

Honourable Chairman, distinguished speakers, ladies and gentlemen, May & Baker, Singapore is proud to play a part in organizing and hosting this symposium. I hope that it is not necessary for me to intro­ duce myself, as Singapore doctors have received my letter of invitation and overseas delegates have received my letter of welcome. It is my very pleasant duty to introduce our Director of Research, Dr J. A. McFadzean, who has come specially to grace this occasion. Dr McFadzean, Sir, may I invite you to say a few words to this gathering of distinguished participants. TanJoo Hock VUl Welcome It is my privilege on behalf of May & Baker to welcome you here today. We have representatives from nine countries - Singapore, Malaysia, Thailand, Hong Kong, Indonesia, Japan, Norway, Sweden and UK. It is appropriate that this Symposium on Cervagem be held in South-east Asia where so much excellent development work was done with this product. Cervagem has resulted from many years of collaborative research and development between May & Baker and the Ono Pharmaceutical Company of Japan. It has been a most happy collaboration from the time the active ingredient ONO-802 was synthesized by the Ono Company. You will hear today of the stage we have reached with the R&D work. Front Matter....Pages i-x Comparison of the pharmacological and biochemical properties of ONO-8O2 (Cervagem) and the naturally occurring prostaglandins....Pages 1-14 Clinical applications of prostaglandins in obstetrics and gynaecology....Pages 15-34 Discussion 1....Pages 35-38 Pre-operative cervical dilatation: comparative study of Cervagem and Sulprostone in first trimester abortion....Pages 39-42 Pre-evacuation cervical dilatation in termination of pregnancy....Pages 43-49 Cervagem clinical trials review. Part I: Pre-operative cervical dilatation in pregnant women....Pages 50-58 Discussion 2....Pages 59-62 Clinical experience with selected prostaglandin analogues in obstetrics and gynaecology....Pages 63-76 Clinical study of Cervagem (ONO-8O2) for application in first and second trimester abortions in Japan....Pages 77-103 Discussion 3....Pages 104-109 Cervagem clinical trials review. Part 2: second trimester therapeutic termination of pregnancy, and other applications....Pages 110-122 Introduction: Cervagem future development....Pages 123-124 Cervagem future development: proposed clinical evaluation by the prescriber....Pages 125-129 Discussion 4 and future developments....Pages 130-132 Chairman’s concluding remarks....Pages 133-133 Preoperative cervical dilatation by vaginal pessaries containing a prostaglandin E 1 analogue (gemeprost, Cervagem)....Pages 134-138 Back Matter....Pages 139-140 Honourable Chairman, distinguished speakers, ladies and gentlemen, May & Baker, Singapore is proud to play a part in organizing and hosting this symposium. I hope that it is not necessary for me to intro duce myself, as Singapore doctors have received my letter of invitation and overseas delegates have received my letter of welcome. It is my very pleasant duty to introduce our Director of Research, Dr J.A. McFadzean, who has come specially to grace this occasion. Dr McFadzean, Sir, may I invite you to say a few words to this gathering of distinguished participants. TanJoo Hock VUl Welcome It is my privilege on behalf of May & Baker to welcome you here today. We have representatives from nine countries - Singapore, Malaysia, Thailand, Hong Kong, Indonesia, Japan, Norway, Sweden and UK. It is appropriate that this Symposium on Cervagem be held in South-east Asia where so much excellent development work was done with this product. Cervagem has resulted from many years of collaborative research and development between May & Baker and the Ono Pharmaceutical Company of Japan. It has been a most happy collaboration from the time the active ingredient ONO-802 was synthesized by the Ono Company. You will hear today of the stage we have reached with the R & D work